Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 6,601–6,700 of 15,747
Fryer, H. A., Geers, D., Gommers, L., Zaeck, L. M., Tan, N. H., Jones, B., Goorhuis, A., Postma, D. F., Visser, L. G., Hogarth, P. M., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106246 · Cited by 14
“1,61,62 Additionally, the mRNA-encoded S protein is stabilized by proline residues, while in adenoviral vector vaccines, the DNA-encoded S protein can be truncated, and the S1 and S2 subunits are not stabilized and can be cleaved.”
RNA research for drug discovery: Recent advances and critical insight
Aja, P. M., Agu, P. C., Ogbu, C. O., Alum, E. U., Fasogbon, I. V., Musyoka, A. M., Ngwueche, W., Egwu, C. O., Tusubira, D., & Ross, K. (2025) · Gene · doi:10.1016/j.gene.2025.149342 · Cited by 17
Coronavirus disease 2019 in children
Levy, E. R., Blumenthal, J. A., & Chiotos, K. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000762 · Cited by 14
Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City
Duerr, R., Dimartino, D., Marier, C., Zappile, P., Wang, G.-Q., Lighter, J. L., Elbel, B. D., Troxel, A., & Heguy, A. (2021) · medRxiv · doi:10.1101/2021.07.05.21259547 · Cited by 52
“The reference sequences were retrieved from a Nextstrain build with North America-focused global subsampling [4] and included 1,361 other US sequences.”
MethodMorgiel, E., Szmyrka−Kaczmarek, M., Madej, M., Sebastian, A., Sokolik, R., Andrasiak, I., Chodyra, M., Walas-Antoszek, M., Korman, L., & Świerkot, J. (2022) · Vaccines · doi:10.3390/vaccines10050710 · Cited by 16
“VAEs are frequently reported in COVID-19 vaccinated individuals, regardless of the type of vaccine, but in most cases, they involve local adverse reactions of mild severity and short duration [30].”
BackgroundResultInfluentialAcute kidney disease following COVID-19 vaccination: a single-center retrospective study
Chen, C., Yang, S.-S., Hsu, Y., Sung, C., Chu, P., Wu, C., Hsu, S., Wang, H.-E., Lee, D.-J., & Lin, S. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1189243 · Cited by 12
“and mRNA-1273 (Moderna) (2, 3), viral vectors such as AZD1222 (Oxford-AstraZeneca), Ad26.”
BackgroundO’Neill, A., Mantri, C. K., Tan, C. W., Saron, W. A. A., Nagaraj, S. K., Kala, M. P., Joy, C. M., Rathore, A. P. S., Tripathi, S., Wang, L., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104924 · Cited by 12
Hall, E. J., Ayers, C. R., Kolkailah, A. A., Rutan, C. M., Walchok, J. G., Williams, J. H., Wang, T. Y., Rodríguez, F., Bradley, S. M., Stevens, L. M., et al. (2023) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.122.009652 · Cited by 12
Ohaeri, C., Thomas, D. R., Salmon, J. E., Cottrell, S. L., Lyons, J., Akbari, A., Lyons, R. A., Torabi, F., Davies, G. I., & Williams, C. J. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2127572 · Cited by 14
Vázquez, N. M., García-Studer, A., Rojas-Gimenez, M., Romero-Barco, C. M., Arija, S. M., Mucientes, A., Velloso-Feijoó, M. L., Godoy‐Navarrete, F. J., Morales-Garrido, P., Redondo‐Rodríguez, R., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092437 · Cited by 12
“Although some initial clinical trials performed with SARS-CoV-2 vaccine excluded patients with SAD [32,33], a subsequent systematic review of several observational studies showed that sero-conversion rates after a full course of mRNA vaccination were very good (>90%) in patients with SAD who did not receive most of th…”
ResultCOVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination
Shah, M. R., Gabel, A., Beers, S., Salaru, G., Lin, Y., & COOPER, D. L. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.11.001 · Cited by 13
Self-citationLiu, X., Sun, Z., Wang, Z., Chen, J., Wu, Q., Zheng, Y., Yang, X., Mo, L., Yan, X., Li, W., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102231 · Cited by 13
Advances of mRNA vaccines for COVID-19: A new prophylactic revolution begins
Weng, Y., & Huang, Y. (2021) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2021.02.005 · Cited by 14
A Critical Analysis of All-Cause Deaths during COVID-19 Vaccination in an Italian Province
Alessandria, M., Malatesta, G., Berrino, F., & Donzelli, A. (2024) · Microorganisms · doi:10.3390/microorganisms12071343 · Cited by 20
“…portion of total deaths, equal to 9,0% in Italy according to the latest available data from ISTAT in the year 2021 [10], even assuming that vaccination can lead to very high reductions in the risk of COVID-19-related deaths [11], this will affect the risk of all-cause deaths only marginally.”
BackgroundKonda, V. C. R., Gokul, T., Poojitha, M. P. M., & Rao, K. U. (2021) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2312 · Cited by 12
Kavosh, A., Ashtari, F., Naghavi, S., Adibi, I., Shaygannejad, V., Karimi, Z., Arabi, S., Rahimi, M., & Mazaheri, S. (2022) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2022.103708 · Cited by 12
COVID-19 Vaccine Booster Uptake and Effectiveness Among US Adults With Cancer
Skarbinski, J., Elkin, E. P., Ziemba, Y. C., Kazemian, E., Wilson, B. M., Siddiqui, H., Schleicher, C. B., Hsiao, C. A., Nugent, J. R., Reckamp, K. L., et al. (2025) · JAMA Oncology · doi:10.1001/jamaoncol.2025.2020 · Cited by 13
Impact of COVID-19 on Clinical Care and Research in Cancer Imaging: Where We Are Now
Luker, G. D., & Boettcher, A. N. (2021) · Radiology Imaging Cancer · doi:10.1148/rycan.2021210003 · Cited by 12
Doshi, P., & Fung, K. (2023) · Journal of Evaluation in Clinical Practice · doi:10.1111/jep.13900 · Cited by 12
BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. Reply.
Walter, E. B., Talaat, K. R., & Gurtman, A. (2022) · PubMed · doi:10.1056/nejmc2118775 · Cited by 13
High viral loads: what drives fatal cases of COVID-19 in vaccinees? – an autopsy study
Hirschbühl, K., Schaller, T., Märkl, B., Claus, R., Sipos, É., Rentschler, L., Maccagno, A., Grosser, B., Kling, E., Neidig, M., et al. (2022) · Modern Pathology · doi:10.1038/s41379-022-01069-9 · Cited by 12
“This study was approved by the internal review board of the medical centerAugsburg (BKF No. 2020–18) and the ethics committee of the University of Munich (Project number 20–426, COVID-19 registry of the University hospital Augsburg, the ethics committee of University Dresden (BO-EK-175052020), the ethics committee of…”
BackgroundInfluentialChang, S., Liu, H., Wu, J., Xiao, W., Chen, S., Qiu, S., Duan, G., Song, H., & Zhang, R. (2022) · Vaccines · doi:10.3390/vaccines10030469 · Cited by 15
“Discussion In this meta-analysis of the VE against COVID-19 infection and VOC from TND studies, in both BNT162b2 and mRNA-1273, partial vaccination had low VE against COVID-19 infection with VE of 61% and 78%, respectively, and full vaccination had significantly higher efficacy against COVID-19 infection than the part…”
ResultCOVID outbreak after the 1st dose of COVID vaccine among the nursing home residents: What happened?
Ye, P., Fry, L., Liu, H., Ledesma, S., & Champion, J. D. (2021) · Geriatric Nursing · doi:10.1016/j.gerinurse.2021.06.022 · Cited by 11
Gonçalves, B. P., Hall, M. D., Jassat, W., Balan, V., Murthy, S., Kartsonaki, C., Semple, M. G., Rojek, A. M., Baruch, J., Reyes, L. F., et al. (2022) · eLife · doi:10.7554/elife.80556 · Cited by 14
“Whilst efforts to develop vaccines that protect against severe disease have been successful (Polack et al., 2020; Voysey et al., 2021; Baden et al., 2021), mutations in the viral genome that lead to ability to escape immunity, and increased transmissibility and/or clinical severity, either via intrinsic virulence or r…”
BackgroundGrape Phytochemicals and Vitamin D in the Alleviation of Lung Disorders
Santa, K. (2022) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530322666220407002936 · Cited by 12
Adults hospitalized with breakthrough COVID‐19 have lower mortality than matched unvaccinated adults
Myers, L. C., Kipnis, P., Greene, J., Lawson, B. L., Escobar, G. J., FIREMAN, B. H., Klein, N. P., & Liu, V. X. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13504 · Cited by 13
Case Report of COVID-19 after Full Vaccination: Viral Loads and Anti-SARS-CoV-2 Antibodies
Komiażyk, M., Walory, J., Gawor, J., Książek, I., Gromadka, R., & Baraniak, A. (2021) · Diagnostics · doi:10.3390/diagnostics11101815 · Cited by 11
“The effectiveness in preventing after clinical trials for the BNT162b2 vaccine was 95% [17].”
BackgroundKandala, B., Plock, N., Chawla, A., Largajolli, A., Robey, S., Watson, K. J., Thatavarti, R., Dubey, S. A., Cheung, S. Y. A., de Greef, R., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104264 · Cited by 12
Liu, Z., Skowron, K., Grudlewska‐Buda, K., & Wiktorczyk-Kapischke, N. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.148949 · Cited by 12
Shiri, T., Evans, M., Talarico, C. A., Morgan, A. R., Mussad, M., Buck, P. O., McEwan, P. C., & Strain, W. D. (2022) · Vaccines · doi:10.3390/vaccines10020140 · Cited by 12
Volkan, E. (2021) · Molecular Biotechnology · doi:10.1007/s12033-021-00353-4 · Cited by 14
“Utilizing this knowledge collectively, Pfizer/BioNtech and Moderna used novel mRNA technology coding S protein, and their vaccine proved to be over 90% efficient in Phase III clinical trials [54].”
MethodKim, S., Oh, T., Lee, H., & Nam, J. (2022) · Materials Chemistry Frontiers · doi:10.1039/d2qm00039c · Cited by 13
Tavazzi, E., Pichiecchio, A., Colombo, E., Rigoni, E., Asteggiano, C., Vegezzi, E., Masi, F., Greco, G., Bastianello, S., & Bergamaschi, R. (2023) · Viruses · doi:10.3390/v15071569 · Cited by 13
“, BNT162b2 by Pfizer BioNTech and mRNA -1273 by Moderna) [18,21,23,92].”
BackgroundQaqish, A., Abbas, M. M., Al‐Tamimi, M., Abbas, M. A., Al-Omari, M., & Alqassieh, R. (2022) · Vaccines · doi:10.3390/vaccines10050643 · Cited by 13
“Moreover, the Pfizer vaccine showed an approximate 95% efficacy rate in protection against subsequent infections with SARS-CoV-2 in terms of symptom severity and need for hospitalization [10].”
BackgroundHuman neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy
Zhou, D., Zhou, R., & Chen, Z. (2021) · Immunotherapy Advances · doi:10.1093/immadv/ltab027 · Cited by 13
“and BioNTech SE) and mRNA-1273 (by Moderna), expressing full S glycoprotein with an efficacy rate of 95% [63, 64] (2) the chimpanzee adenovirus-vectored vaccine, named ChAdOx1 nCoV-19 (by the Oxford University and AstraZeneca Inc.”
Pratò, S., Paladino, M. E., Riva, M. A., & Belingheri, M. (2021) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0000000000002389 · Cited by 13
“However, it is not yet clear whether the vaccine also prevents asymptomatic infection.(8) Some authors have noted previously vaccinated asymptomatic patients who tested positive on reverse transcription—polymerase chain reaction (RTPCR) tests.”
BackgroundSubramanian, V. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad152 · Cited by 11
Jian, Z., Wang, M., Jin, X., & Wei, X. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.731962 · Cited by 16
“COVID-19 first emerged in December 2019 and has become a worldwide pandemic currently (1).”
BackgroundZhu, T., Pawlak, S., Toussi, S. S., Hackman, F., Thompson, K. M., Song, W., Salageanu, J., Winter, E., Shi, H., Winton, J. A., et al. (2022) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1174 · Cited by 13
The Role of Sampling in Medicine
Msaouel, P. (2023) · Harvard Data Science Review · doi:10.1162/99608f92.bc6818d3 · Cited by 15
Mallhi, T. H., Khan, Y. H., Butt, M. H., et al. (2022) · Medicina · doi:10.3390/medicina58121799 · Cited by 12
Rammauro, F., Carrión, F., Olivero‐Deibe, N., Fló, M., Ferreira, A., Pritsch, O., & Bianchi, S. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.07.023 · Cited by 14
“In February 2021, the Ministry of Public Health of Uruguay authorized the emergency use of CoronaVac [3] (600 SU of inactivated virus per dose) and BNT162b2 [4] (30 lg per dose) vaccines in two doses administrated 28 days apart.”
Vaccine-induced interstitial lung disease: a rare reaction to COVID-19 vaccination
DeDent, A. M., & Farrand, E. D. (2021) · Thorax · doi:10.1136/thoraxjnl-2021-217985 · Cited by 12
Design and Immunological Properties of the Novel Subunit Virus-like Vaccine against SARS-CoV-2
Krasilnikov, I. V., Kudriavtsev, A. V., Vakhrusheva, A., Frolova, M. E., Ivanov, A. V., Stukova, M., Romanovskaya-Romanko, E., Vasilyev, K., Mushenkova, N. V., & Isaev, A. A. (2022) · Vaccines · doi:10.3390/vaccines10010069 · Cited by 12
“According to reported clinical data, the efficacy of current vaccines varies from 79% [9] to 95% [10] thus fulfilling the target product profile for COVID-19 vaccines suggested by WHO, with an estimated 70% endpoint [11].”
BackgroundÖzüdoğru, O., Acer, Ö., & Bahçe, Y. G. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27778 · Cited by 11
Jamaati, H., Karimi, S., Ghorbani, F., Panahi, Y., Hosseini‐Baharanchi, F. S., Hajimoradi, M., Malek, R., Noorali, S., Mokhtari, M., Khoundabi, B., et al. (2023) · Journal of Medical Virology · doi:10.1002/jmv.28607 · Cited by 14
“Lopez Bernal et al.21 observed a 51% decrease in COVID‐19‐related risk of death by a single dose of vaccination or 95% protection after two doses of vaccination with BNTn2b.22 In another study on non‐ICU admitted patients, 79%, 13%, and 8% of deaths were reported in the unvaccinated, partially‐, and fully‐vaccinated p…”
BackgroundXu, A. M., Li, D., Ebinger, J. E., Mengesha, E., Elyanow, R., Gittelman, R., Chapman, H., Joung, S. Y., Botwin, G. J., Pozdnyakova, V., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.880190 · Cited by 12
“S by Janssen/ Johnson&Johnson) and mRNA vaccines (BNT162b2 by Pfizer/ BioNTech, mRNA-1273 by Moderna/NIH) (11, 12) are both in wide use in the United States, although there may be some advantages of the latter in safety, pharmacokinetics, and manufacturing (13, 14).”
BackgroundHonda‐Okubo, Y., Antipov, A., André, G. O., Barati, S., Kafi, H., & Petrovsky, N. (2023) · Immunology · doi:10.1111/imm.13661 · Cited by 14
Optic neuritis following COVID-19 vaccination: Do autoimmune diseases play a role?
Pirani, V., Pelliccioni, P., Carpenè, M. J., et al. (2022) · European Journal of Ophthalmology · doi:10.1177/11206721221118736 · Cited by 12
“The Pfizer-BioNTech COVID-19 Vaccine BNT162b2 is a nucleoside-modified RNA vaccine that has shown to be safe and 95% effective against COVID-19.”
BackgroundInfluentialCOVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
Kampouri, E., Hill, J. A., & Dioverti, M. V. (2023) · Transplant Infectious Disease · doi:10.1111/tid.14144 · Cited by 15
“52,55 7, 60 However , immunological”
Efficacy and Safety of AZD1222, BNT162b2 and mRNA-1273 vaccines against SARS-CoV-2
Alimehmeti, I. (2021) · Albanian Journal of Trauma and Emergency Surgery · doi:10.32391/ajtes.v5i1.178 · Cited by 13
Giant cell myocarditis after first dose of BNT162b2 – a case report
Hirsch, V. G., Schallhorn, S., Zwadlo, C., Diekmann, J., Länger, F. P., Jonigk, D. D., Kempf, T., Schultheiß, H., & Bauersachs, J. K. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2590 · Cited by 13
Assembling the RNA therapeutics toolbox
Teng, M., Xia, Z. J., Lo, N., Daud, K., & He, H. H. (2024) · Medical Review · doi:10.1515/mr-2023-0062 · Cited by 14
Humoral profiles of toddlers and young children following SARS-CoV-2 mRNA vaccination
Nziza, N., Deng, Y., Wood, L., Dhanoa, N., Dulit-Greenberg, N., Chen, T., Kane, A. S., Swank, Z., Davis, J. P., Demokritou, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45181-7 · Cited by 16
SARS-CoV-2 membrane protein induces neurodegeneration via affecting Golgi-mitochondria interaction
Wang, F., Han, H., Wang, C., Wang, J., Peng, Y., Chen, Y., He, Y., Deng, Z., Li, F., Rong, Y. S., et al. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00458-1 · Cited by 14
Beerlage, A., Leuzinger, K., Valore, L., et al. (2022) · Transplant Infectious Disease · doi:10.1111/tid.13828 · Cited by 12
Takano, T., Morikawa, M., Adachi, Y., Kabasawa, K., Sax, N., Moriayma, S., Sun, L., Isogawa, M., Nishiyama, A., Onodera, T., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3956654 · Cited by 12
Kanjanapan, Y., Blinman, P. L., Underhill, C. R., Karikios, D. J., Segelov, E., & Yip, D. (2021) · Internal Medicine Journal · doi:10.1111/imj.15339 · Cited by 10
Wang, Y., Samreen, S., Ullah, S., et al. (2023) · Results in Physics · doi:10.1016/j.rinp.2023.106889 · Cited by 12
Qiu, X., Yang, Y., Ma, Q., Zheng, B., Chen, Z., Wu, F., Zhou, B., & Xiong, H. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c19387 · Cited by 16
Capone, F., Rossi, M., Cruciani, A., Motolese, F., Pilato, F., & Lazzaro, V. D. (2022) · Neural Regeneration Research · doi:10.4103/1673-5374.346539 · Cited by 16
“In many countries, policymakers decided to make mRNA vaccines the first choice for vulnerable people, including PwMS, because of their safety profile, the low production cost, the ready availability, and their higher efficacy (Polack et al., 2020).”
Waisner, H., Grieshaber, B., Saud, R., Henke, W., Stephens, E., & Kalamvoki, M. (2022) · bioRxiv · doi:10.1128/spectrum.03707-22 · Cited by 8
“Several highly effective vaccines have received use authorization, but the slow global vaccination rate and accumulation of adaptive mutations in different proteins of the virus, particularly the Spike protein, yield novel variants with different immunoevasion properties (2-5).”
BackgroundSteffes, V. M., Zhang, Z., Ewert, K. K., & Safinya, C. R. (2023) · Langmuir · doi:10.1021/acs.langmuir.3c02664 · Cited by 11
Maeda, H., Saito, N., Igarashi, A., Ishida, M., Terada, M., Masuda, S., Osawa, R., Hosokawa, N., Nakashima, K., Kamura, H., et al. (2024) · Expert Review of Vaccines · doi:10.1080/14760584.2024.2310807 · Cited by 10
“…negative result [3]; episodes with negative test results within three weeks before or after a positive test result [4]; for multiple positive episodes during the study period, only the first episode was included; and [5] we included a maximum of three negative test results for each individual.”
Kurbegov, D., Bruinooge, S. S., Lei, X. J., Kirkwood, M. K., Dickson, N. R., Hattiangadi, T., Mileham, K. F., Patrick, A. L., Williams, J. H., Kaltenbaugh, M. W., et al. (2023) · Cancer · doi:10.1002/cncr.34726 · Cited by 11
“rollout based on having a high‐risk condition.(1,25) To our knowledge, this is the first large‐scale analysis of patterns and factors associated with vaccination uptake among people in cancer treatment who were infected with SARS–CoV‐2.”
BackgroundMethodRace with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2
Lee, K.-M., Lin, S., Wu, C.-J., & Kuo, R. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.01.002 · Cited by 15
“The results showed that the incidence of severe adverse events was low and that the efficacy for preventing COVID-19 was 95% [53].”
Duarte, M. B. O., Leal, F. R. P., Argenton, J. L. P., et al. (2021) · Infectious Agents and Cancer · doi:10.1186/s13027-021-00406-y · Cited by 11
Haimei, M. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211040110 · Cited by 12
Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases
Ramirez, G. A., Asperti, C., Cucca, V., & Yacoub, M. (2021) · Vaccines · doi:10.3390/vaccines9101147 · Cited by 12
“Adverse events were relatively frequent after the first, second or both doses in patients with rheumatic diseases, consistent with data from the general population [25].”
BackgroundResultNew-onset Graves’ disease following SARS-CoV-2 vaccination: a case report
Manta, R., Martin, C., Muls, V., & Poppe, K. G. (2022) · European Thyroid Journal · doi:10.1530/etj-22-0049 · Cited by 12
Humoral Responses Elicited after a Fifth Dose of SARS-CoV-2 mRNA Bivalent Vaccine
Tauzin, A., Beaudoin-Bussières, G., Benlarbi, M., Nayrac, M., Bo, Y., Gendron‐Lepage, G., Medjahed, H., Perreault, J., Gokool, L., Arlotto, P., et al. (2023) · Viruses · doi:10.3390/v15091926 · Cited by 11
Burns, J., Rivers, P. S., LeClair, L. B., Jovel, K. S., Rai, R. P., Lowe, A. A., Edwards, L., Khan, S. R., Mathenge, C., Ferraris, M., et al. (2022) · JMIR Research Protocols · doi:10.2196/37929 · Cited by 10
The ethics behind mandatory COVID-19 vaccination post-Omicron: The South African context
Moodley, K. (2022) · South African Journal of Science · doi:10.17159/sajs.2022/13239 · Cited by 16
Walmsley, S. L., Szadkowski, L., Wouters, B. G., Clarke, R., Colwill, K., Rochon, P. A., Brudno, M., Ravindran, R., Raboud, J., McGeer, A., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106506 · Cited by 13
Coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness in asymptomatic healthcare workers
Knobel, P., Serra, C., Grau, S., Ibañez, R., Díaz, P., Ferrández, O., Villar, R., Lopez, A. F., Fulquet, N. P., Horcajada, J. P., et al. (2021) · Infection Control and Hospital Epidemiology · doi:10.1017/ice.2021.287 · Cited by 11
Hoffmann, M., Gerlach, S., Takamiya, M., Tarazi, S., Hersch, N., Csiszár, Á., Springer, R., Dreissen, G., Scharr, H., Rastegar, S., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041210 · Cited by 11
“Vaccination strategies also benefit from mRNA technologies [3], as shown for the most promising strategy against the SARS-CoV2 [4,5].”
BackgroundBughin, J., Cincera, M., Kiepfer, E., Reykowska, D., Philippi, F., Żyszkiewicz, M., Ohme, R. K., & Frank, D. (2022) · The European Journal of Health Economics · doi:10.1007/s10198-022-01450-0 · Cited by 11
“[33]—and the claim made over the effectiveness of the Russian vaccine, Sputnik V6), and a case of just 50%.”
BackgroundSARS-CoV-2 in dialysis patients and the impact of vaccination
Moore, L. R., Al-Jaddou, N., Wodeyar, H., et al. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02940-2 · Cited by 11
“In contrast to the general population in whom both the BNT162b2 (Pfizer BioNTech) and the ChAdOx1 (Astra Zeneca) vaccines have proved effective [6, 7], very little is known whether such a strategy translates into reduced infection or transmission rates in the ICHD population.”
ResultJacob, S. S., Bridgeman, M. B., Kim, H. C., Toscani, M., Kohler, R. E., Shiau, S., Jimenez, H. R., Barone, J. A., & Narayanan, N. (2021) · Pharmacy · doi:10.3390/pharmacy9030131 · Cited by 11
Du, J., Su, Y., Wang, R., Dong, E., Cao, Y., Zhao, W., & Gong, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1118378 · Cited by 15
Tedeschi, A., Camilli, M., Ianni, U., Tavecchia, G., Palazzini, M., Cartella, I., Gentile, P., Quattrocchi, G., Spanò, F. M., Cipriani, M., et al. (2022) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2022.101002 · Cited by 12
“BNT162b2 Pfizer BioNTech mRNASarsCoV-2 vaccines are effective in preventing COVID-19 with an excellent safety profile [1], even if cardiac adverse events have been rarely reported, especially acute myocarditis [2,3].”
Lucca, F., Bezzerri, V., Danese, E., Olioso, D., Peserico, D., Boni, C., Cucchetto, G., Montagnana, M., Tridello, G., Meneghelli, I., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020908 · Cited by 12
“The high efficacy of mRNA-based vaccines has been observed in different Phase 3 clinical trials, and has also been documented by real-world data, indicating that both BNT162b2 [11,15] and mRNA-1273 [12,16] have efficacy against different circulating SARS-CoV-2 variants [17,18].”
BackgroundPure sensitive chronic inflammatory axonal polyneuropathy following Pfizer COVID-19 vaccine
Luca, A., Squillaci, R., Terravecchia, C., et al. (2021) · Neurological Sciences · doi:10.1007/s10072-021-05696-z · Cited by 11
Bhopal, S., Olabi, B., & Bhopal, R. S. (2020) · Public Health · doi:10.1016/j.puhe.2021.01.011 · Cited by 19
(2021) · doi:10.1101/2021.03.05.21252590 · Cited by 139
Wang, T. L., Krishnamurti, T., Bernard, M., Lopa, S., Quinn, B., & Simhan, H. N. (2022) · Behavioral Medicine · doi:10.1080/08964289.2021.2023456 · Cited by 10
Shabani, M., Shobeiri, P., Nouri, S., Moradi, Z., Amenu, R. A., Nejad, M.-M. M., & Rezaei, N. (2024) · European journal of medical research · doi:10.1186/s40001-024-01639-4 · Cited by 11
“Data on SARS-CoV-2 vaccine safety in this vulnerable population are limited as they were widely excluded from the original vaccine trials; however, it is increasingly investigated through different clinical trials [15, 16].”
BackgroundSibai, M., Solis, D., Röltgen, K., Stevens, B., Mfuh, K. O., Sahoo, M. K., Shi, R., Zehnder, J. L., Boyd, S. D., & Pinsky, B. A. (2021) · Journal of Clinical Virology · doi:10.1016/j.jcv.2021.104818 · Cited by 11
Riley, S., Wang, H., Eales, O. D., Walters, C. E., Ainslie, K. E. C., Atchison, C. J., Fronterrè, C., Diggle, P. J., Ashby, D., Donnelly, C. A., et al. (2021) · medRxiv · doi:10.1101/2021.01.20.21250158 · Cited by 10
Durier, C., Ninove, L., Lefebvre, M., Radenne, A., Desaint, C., Ropers, J., Bauer, R., Lebbah, S., Carette, D., Lachâtre, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-24409-w · Cited by 10
Heinen, N., Marheinecke, C. S., Bessen, C., Blazquez‐Navarro, A., Roch, T., Stervbo, U., Anft, M., Plaza‐Sirvent, C., Buße, S., Klöhn, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1062210 · Cited by 10
Gilbert, J., Ermilova, I., Fornasier, M., Skoda, M., Fragneto, G., Swenson, J., & Nylander, T. (2023) · Nanoscale · doi:10.1039/d3nr03308b · Cited by 12
Hatfield, K. M., Baggs, J. M., Wolford, H. M., Fang, M., Sattar, A. A., Montgomery, K. S., Jin, S., Jernigan, J. A., & Pilishvili, T. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac562 · Cited by 12
Arashiro, T., Miwa, M., Nakagawa, H., Takamatsu, J., Oba, K., Fujimi, S., Kikuchi, H., Iwasawa, T., Kanbe, F., Oyama, K., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2023.12.033 · Cited by 11
Bellavita, R., Braccia, S., Piccolo, M., Białecki, P., Ferraro, M. G., Graziano, S. F., Esposito, E., Donadio, F., Bryszewska, M. J., Irace, C., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.139219 · Cited by 12
Graham, S., Tessier, E., Stowe, J., Bernal, J. L., Parker, E. P. K., Nitsch, D., Miller, E., Andrews, N. J., Walker, J. L., & McDonald, H. I. (2023) · Nature Communications · doi:10.1038/s41467-023-39674-0 · Cited by 12
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.